CDK9 and B-cell chronic lymphocytic leukemia: As a potent inhibitor of both CDK 7 and CDK9, SNS-032 has been demonstrated to effectively kill chronic lymphocytic leukemia (CLL) cells via blockage of phosphorylation of RNA polymerase II and inhibition of RNA synthesis in vitro regardless of prognostic indicators and treatment history [17].